CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Restricted Cash and Cash Equivalents, Noncurrent
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Restricted Cash and Cash Equivalents, Noncurrent of $1.11 million as of 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2023-02-22
- 2022-12-31: Restricted Cash and Cash Equivalents, Noncurrent $1.11M.
- 2022-09-24: Restricted Cash and Cash Equivalents, Noncurrent $1.10M.
- 2022-06-25: Restricted Cash and Cash Equivalents, Noncurrent $1.09M.
- 2022-03-26: Restricted Cash and Cash Equivalents, Noncurrent $1.11M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2022-12-31 | $1.11M 10-K · filed 2023-02-22 |
| 2022-09-24 | $1.10M 10-Q · filed 2022-11-02 |
| 2022-06-25 | $1.09M 10-Q · filed 2022-08-03 |
| 2022-03-26 | $1.11M 10-Q · filed 2022-05-04 |
| 2021-12-25 | $1.08M 10-K · filed 2023-02-22 |
| 2020-12-26 | $1.62M 10-K · filed 2023-02-22 |
| 2019-12-28 | $1.60M 10-K · filed 2022-02-16 |
| 2018-12-29 | $1.41M 10-K · filed 2021-02-17 |
| 2017-12-30 | $1.95M 10-K · filed 2020-02-11 |
| 2016-12-31 | $1.74M 10-K · filed 2019-02-13 |
| 2015-12-26 | $1.75M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |